DOCSLIB.ORG

What Are the Best Prophylactic Drugs for Migraine?

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
What Are the Best Prophylactic Drugs for Migraine? Evidence-based answers from the Family Physicians Inquiries Network Jonathon M. Firnhaber, MD Brody School of Medicine at East Carolina University, What are the best prophylactic Greenville, NC Katherine Rickett, drugs for migraine? MSLS, MSEd Laupus Health Sciences Library, East Carolina University, Greenville, NC EVIDENCE-BASED ANSWER Beta-blockers with in- trinsic sympathomimetic Beta-blockers without intrinsic sympathomimetic activity (acebutolol, alpre- A activity, amitriptyline, divalproex sodium/sodium nolol, oxprenolol, pindo- valproate, and topiramate are the most eff ective drugs for lol) appear to be ineff ective preventing episodic migraine (strength of recommendation: for migraine prevention.4 A, multiple, well-designed, randomized controlled trials Propranolol [RCTs]). Amitriptyline works and timolol have better than propranolol consistently for some migraines demonstrated Evidence summary Amitriptyline is the most often studied anti- effi cacy for Many medications have been evaluated for depressant and the only one with consistent preventing migraine prophylaxis. However, very few head- support for effi cacy in preventing migraine. A episodic to-head trials of more than 2 drugs have been 1981 trial found amitriptyline to be more ef- migraine. published, and no recent meta-analyses of fective than propranolol in mixed migraine- available drug classes have been performed. tension-type headache, whereas propranolol Th e most commonly evaluated outcome is a was more eff ective for migraine alone.5 50% reduction in headache frequency. Some support for fl uoxetine, Propranolol and timolol none for similar drugs offer consistent prevention Limited evidence exists for the use of fl uox- Propranolol and timolol have consistently etine, 20 mg daily. A small 1999 study of pa- demonstrated effi cacy for preventing episodic tients with migraine without aura found a 57% migraine. In a 1991 meta-analysis, proprano- reduction in total pain index—a value based lol resulted in a 44% reduction in the head- on pain intensity and hours of headache per ache index—a composite score that takes into month—with fl uoxetine compared with an in- account both intensity and duration—com- signifi cant 31% reduction with placebo.6 pared with a 14% reduction for placebo.1 No evidence from controlled trials sup- ports the use of fl uvoxamine, paroxetine, ser- Less evidence supports traline, phenelzine, venlafaxine, mirtazapine, other beta-blockers trazodone, or bupropion.4 Atenolol, metoprolol, and nadolol have dem- onstrated a moderate eff ect, but less evidence Divalproex sodium, exists to support their use.2 A recent trial sodium valproate are effective comparing metoprolol and nebivolol demon- Divalproex sodium and sodium valproate strated a positive response—defi ned as a 50% show strong, consistent evidence of effi cacy; reduction in headache frequency—to each they may be particularly useful for patients drug at 14 weeks (57% of metoprolol-treated with prolonged or atypical migraine aura.4 and 50% of nebivolol-treated patients), but Initial studies of delayed-release divalproex at 3 noted that nebivolol was better tolerated. doses ranging from 500 to 1500 mg daily found 608 THE JOURNAL OF FAMILY PRACTICE | NOVEMBER 2009 | VOL 58, NO 11 608_JFP1109 608 10/19/09 11:46:01 AM TABLE Recommended drugs for migraine prophylaxis13 Drug Dose Comments Propranolol 80-240 mg/d May cause fatigue. When used in combination with rizatriptan, give a lower dose of rizatriptan. Timolol 20-30 mg/d As with propranolol, may cause fatigue. Avoid β-blockers in patients with asthma or Raynaud’s disease. Amitriptyline 25-150 mg/d Drowsiness, weight gain, and signifi cant anticholinergic adverse events are common. Divalproex sodium; 500-1500 Side effects include nausea, drowsiness, weight gain, hair loss, mg/d; and tremor. Hepatotoxicity, pancreatitis, and hyperammonemia Sodium valproate 800-1500 have been reported rarely. Pregnancy category D. mg/d Topiramate 100-200 mg/d Paresthesia is the most common adverse event; fatigue, nausea, anorexia, and cognitive symptoms are less common. Carbonic anhydrase inhibition may cause metabolic acidosis. Acute myopia and angle closure glaucoma are rare events. Amitriptyline is more effective than propranolol for mixed that 44% of divalproex-treated patients re- drugs for migraine prophylaxis found that migraine- ported a 50% reduction in migraine frequen- anticonvulsants, as a class, reduce migraine tension-type cy, compared with 21% in the placebo group frequency by about 1.3 attacks per 28 days headache, (number needed to treat [NNT]=4).7 when compared with placebo (based on whereas A more recent study of the extended- 10 trials [N=902]). When analyzing data on propranolol release form of divalproex sodium demon- relative frequency of migraines, data from 13 works better strated a 4-week reduction in headache rate trials (N=1773) were combined and showed for migraine to 1.2 from a baseline of 4.4, compared with that anticonvulsants more than doubled the alone. a decrease of 0.6 for placebo (95% confi dence number of patients with a 50% or greater de- interval [CI] of treatment diff erence, 0.2-1.2).8 crease in migraine frequency relative to pla- cebo (relative risk=2.25; 95% CI, 1.79-2.84; Topiramate may decrease frequency NNT=3.9; 95% CI, 3.4-4.7).11 as much as propranolol Topiramate has signifi cantly reduced the mean Other drugs to keep on your radar frequency of episodic migraine at doses of 100 Agents available in the United States that have to 200 mg daily and also improved second- at least limited evidence supporting their use ary end points, including number of migraine to prevent episodic migraine include gaba- days per month, use of acute medication, and pentin, lisinopril, candesartan, memantine, daily activity.9 One study found that topiramate ribofl avin, magnesium, feverfew, coenzyme 100 mg daily had comparable effi cacy to pro- Q10, butterbur, and melatonin. pranolol 160 mg daily; both drugs decreased Drugs so far proved ineff ective in pre- monthly migraine frequency to 1.6 from a base- venting episodic migraine include clonidine, line of 4.9 with topiramate and 5.1 with pro- carbamazepine, clonazepam, vigabatrin, ox- pranolol (95% CI for the pair-wise diff erence of carbazepine, zonisamide, lamotrigine, nife- topiramate minus propranolol, −0.58 to 0.60).10 dipine, and acetazolamide. Botulinum toxin type A given by intramuscular injection in the Anticonvulsants also reduce head and neck region has demonstrated limit- migraine frequency ed effi cacy in chronic headache disorders, but A 2004 Cochrane review of anticonvulsant doesn’t prevent episodic migraine.12 CONTINUED JFPONLINE.COM VOL 58, NO 11 | NOVEMBER 2009 | THE JOURNAL OF FAMILY PRACTICE 609 609_JFP1109 609 10/19/09 11:46:05 AM Recommendations Th e 2000 guidelines of the American Association of Neurology address Group 1 (fi rst-line) drugs and Group 2 drugs: ❚ Group 1 drugs (medium to high effi - cacy, good strength of evidence, and a range of severity [mild to moderate] and frequency [infrequent to frequent] of side eff ects) include amitriptyline, divalproex sodium, proprano- lol, and timolol. ❚ Group 2 drugs (lower effi cacy than Group 1, or limited strength of evidence, and SEE THE BEST THAT CLEVELAND HAS TO OFFER. mild to moderate side eff ects) include aspirin (but not combination products), atenolol, feno- Family Medicine profen, feverfew, fl urbiprofen, fl uoxetine, ga- bapentin, guanfacine, ketoprofen, magnesium, The Department of Family Medicine at the Cleveland Clinic is mefenamic acid, metoprolol, nadolol, naprox- seeking board certified/eligible Family Medicine Physicians for 13 outpatient positions in our Family Health Centers located en, nimodipine, verapamil, and vitamin B2. throughout the Cleveland area. The positions include the Topiramate was still under study when the opportunity to teach medical students from the Cleveland Clinic Lerner College of Medicine, precept Family Medicine Residents and guidelines were released and wasn’t approved to participate in practice based research. by the US Food and Drug Administration for Cleveland Clinic is an equal opportunity employer and is committed migraine prophylaxis until 2004. Th e 2000 to increasing the diversity of its faculty. It welcomes nominations of and applications from women and members of minority groups, as guidelines are undergoing revision. well as others who would bring additional dimensions to its research, teaching, and clinical missions. Cleveland Clinic is a smoke/drug free work environment. Interested candidates should forward a current copy of their CV in WORD format to the attention of: JoeVitale, Senior Director, References Office of Physician Recruitment, Professional Staff Affairs; 1. Holroyd KA, Penzien DB, Cordingley GE. Propranolol in the [email protected] or apply online at www.ccf.org management of recurrent migraine: a meta-analytic review. Headache. 1991;31:333-340. 2. Silberstein SD, Goadsby PJ. Migraine: preventive treatment. Cephalalgia. 2002;22:491-512. 3. Schellenberg R, Lichtenthal A, Wöhling H, et al. Nebivolol and metoprolol for treating migraine: an advance on -blocker treat- ment? Headache. 2008;48:118-125. ADVERTISERS AND PRODUCTS 4. Snow V, Weiss K, Wall EM, et al. Pharmacologic management of acute attacks of migraine and prevention of migraine headache. Ann Intern Med. 2002;137:840-849. CVD/HIV Conference ............................................................. 601 5. Mathew NT. Prophylaxis of migraine and mixed headache: a ran- domized
Load more

Recommended publications
  • Product List March 2019 - Page 1 of 53
    Wessex has been sourcing and supplying active substances to medicine manufacturers since its incorporation in 1994. We supply from known, trusted partners working to full cGMP and with full regulatory support. Please contact us for details of the following products. Product CAS No. ( R)-2-Methyl-CBS-oxazaborolidine 112022-83-0 (-) (1R) Menthyl Chloroformate 14602-86-9 (+)-Sotalol Hydrochloride 959-24-0 (2R)-2-[(4-Ethyl-2, 3-dioxopiperazinyl) carbonylamino]-2-phenylacetic 63422-71-9 acid (2R)-2-[(4-Ethyl-2-3-dioxopiperazinyl) carbonylamino]-2-(4- 62893-24-7 hydroxyphenyl) acetic acid (r)-(+)-α-Lipoic Acid 1200-22-2 (S)-1-(2-Chloroacetyl) pyrrolidine-2-carbonitrile 207557-35-5 1,1'-Carbonyl diimidazole 530-62-1 1,3-Cyclohexanedione 504-02-9 1-[2-amino-1-(4-methoxyphenyl) ethyl] cyclohexanol acetate 839705-03-2 1-[2-Amino-1-(4-methoxyphenyl) ethyl] cyclohexanol Hydrochloride 130198-05-9 1-[Cyano-(4-methoxyphenyl) methyl] cyclohexanol 93413-76-4 1-Chloroethyl-4-nitrophenyl carbonate 101623-69-2 2-(2-Aminothiazol-4-yl) acetic acid Hydrochloride 66659-20-9 2-(4-Nitrophenyl)ethanamine Hydrochloride 29968-78-3 2,4 Dichlorobenzyl Alcohol (2,4 DCBA) 1777-82-8 2,6-Dichlorophenol 87-65-0 2.6 Diamino Pyridine 136-40-3 2-Aminoheptane Sulfate 6411-75-2 2-Ethylhexanoyl Chloride 760-67-8 2-Ethylhexyl Chloroformate 24468-13-1 2-Isopropyl-4-(N-methylaminomethyl) thiazole Hydrochloride 908591-25-3 4,4,4-Trifluoro-1-(4-methylphenyl)-1,3-butane dione 720-94-5 4,5,6,7-Tetrahydrothieno[3,2,c] pyridine Hydrochloride 28783-41-7 4-Chloro-N-methyl-piperidine 5570-77-4
    [Show full text]
  • Acebutolol Hydrochloride Eq 200 Mg Base, Capsule, Oral, 100 0.4612 B Eq 400 Mg Base, Capsule, Oral, 100 0.6713 B
    TRANSMITTAL NO. 37 - FEDERAL UPPER LIMIT DRUG LIST NOVEMBER 20, 2001 The following list of multiple source drugs meets the criteria set forth in 42 CFR 447.332 and Section 1927(e) of the Social Security Act, as amended by OBRA 1993. Payment for multiple source drugs identified and listed below must not exceed, in the aggregate, payment levels determined by applying to each drug entity a reasonable dispensing fee (established by the State and specified in the State plan), plus an amount based on the limit per unit which CMS has determined to be equal to 150 percent applied to the lowest price listed (in package sizes of 100 units, unless otherwise noted) in any of the published compendia of cost information of drugs. The listing is based on data current as of April 2001 from First Data Bank (Blue Book), Medi- Span, and the Red Book. This list does not reference the commonly known brand names. However, the brand names are included in the electronic FUL listing provided to the state agencies. The FUL price list and electronic listing are available at http://www.cms.hhs.gov/Reimbursement/05_FederalUpperLimits.asp. In accordance with current policy, Federal financial participation will not be provided for any drug on the FUL listing for which the FDA has issued a notice of an opportunity for a hearing as a result of the Drug Efficacy Study and Implementation (DESI) program, and which has been found to be a less than effective or is identical, related or similar (IRS) to the DESI drug. The DESI drug is identified by the Food and Drug Administration or reported by the drug manufacturer for purposes of the Medicaid drug rebate program.
    [Show full text]
  • Therapeutic Class Overview Beta-Adrenergic Blocking Agents
    Therapeutic Class Overview Beta-adrenergic Blocking Agents INTRODUCTION Approximately 92.1 million American adults have at least 1 type of cardiovascular disease according to the American Heart Association (AHA) Heart Disease and Stroke Statistics 2018 update. From 2003 to 2015, mortality associated with cardiovascular disease declined 25.5% (Benjamin et al 2018). Beta-adrenergic blocking agents (beta-blockers) are a group of drugs that block the sympathomimetic effects of catecholamines on beta receptors. This results in negative inotropic and chronotropic effects and relaxation of smooth muscle. Beta-blockers have varied pharmacologic properties. ○ Cardioselective beta-blockers preferentially interact with beta1-receptors, which are predominantly found in the heart. Non-cardioselective beta-blockers also interact with beta2-receptors found on smooth muscle in the lungs, blood vessels, and other tissues. The cardioselectivity of beta-blockers is dose dependent; therefore, beta2 blockade can occur at higher doses with certain cardioselective agents. ○ Some beta-blockers (acebutolol and pindolol) have intrinsic sympathomimetic activity (ISA), which may result in a lower incidence of bradycardia and bronchoconstriction (Facts and Comparisons 2018). In addition, some beta- blockers (nebivolol and propranolol) have higher lipophilicity, which may increase the risk for central nervous system- related adverse events (Facts and Comparisons 2018). ○ Carvedilol and labetalol also block alpha-adrenergic receptors and may reduce peripheral resistance more than other beta-blockers (Clinical Pharmacology 2018). Specific indications for the beta-blockers vary by product. Most beta-blockers (all except sotalol) are approved to treat hypertension (HTN). The 2017 American College of Cardiology (ACC)/AHA clinical practice guideline defines HTN as blood pressure (BP) ≥ 130/80 mm Hg (Whelton et al 2017).
    [Show full text]
  • Slow Trasicor Tablets 160Mg (Oxprenolol Hydrochloride)
    Prescribing information slow trasicor tablets 160mg (oxprenolol hydrochloride) Presentation: Contains 160mg oxprenolol hydrochloride in a danger of cardiac arrest, a calcium antagonist of the verapamil sustained-release tablet type must not be administered intravenously to patients already indication: Hypertension and angina pectoris (long-term receiving treatment with a beta-blocker. Beta-blockers should be prophylaxis) discontinued in patients who are at increased risk for anaphylaxis. Dosage and administration: Oral tablets to be swallowed whole. interactions: Verapamil, diltiazem, disopyramide, quinidine, Adults: Hypertension: 160mg once daily. If necessary, the dosage amiodarone, adrenaline, noradrenaline, isoprenaline, ephedrine, can be raised to 320mg. Angina pectoris: 160mg once daily. If phenylephrine, clonidine, guanethidine, reserpine, oral antidiabetic necessary, the dosage can be raised to 320mg. Elderly: No special drugs, NSAIDs, cimetidine, ergot alkaloids, anaesthetics, digitalis dosage regimen is necessary but concurrent hepatic insufficiency glycosides, lidocaine and alcohol. should be taken into account. Children: Not recommended. Pregnancy and lactation: Use with caution during pregnancy contraindications: Hypersensitivity to oxprenolol and related especially in the first 3 months. Breast feeding is not recommended. derivatives, cross-sensitivity to other beta-blockers or to any of the Undesirable effects: Very Common: Dry mouth, constipation. excipients, cardiogenic shock, second or third degree atrioventricular Common:
    [Show full text]
  • Fatal Toxicity of Antidepressant Drugs in Overdose
    BRITISH MEDICAL JOURNAL VOLUME 295 24 OCTOBER 1987 1021 Br Med J (Clin Res Ed): first published as 10.1136/bmj.295.6605.1021 on 24 October 1987. Downloaded from PAPERS AND SHORT REPORTS Fatal toxicity of antidepressant drugs in overdose SIMON CASSIDY, JOHN HENRY Abstract dangerous in overdose, thus meriting investigation of their toxic properties and closer consideration of the circumstances in which A fatal toxicity index (deaths per million National Health Service they are prescribed. Recommendations may thus be made that prescriptions) was calculated for antidepressant drugs on sale might reduce the number offatalities. during the years 1975-84 in England, Wales, and Scotland. The We used national mortality statistics and prescription data tricyclic drugs introduced before 1970 had a higher index than the to compile fatal toxicity indices for the currently available anti- mean for all the drugs studied (p<0-001). In this group the depressant drugs to assess the comparative safety of the different toxicity ofamitriptyline, dibenzepin, desipramine, and dothiepin antidepressant drugs from an epidemiological standpoint. Owing to was significantly higher, while that ofclomipramine, imipramine, the nature of the disease these drugs are particularly likely to be iprindole, protriptyline, and trimipramine was lower. The mono- taken in overdose and often cause death. amine oxidase inhibitors had intermediate toxicity, and the antidepressants introduced since 1973, considered as a group, had significantly lower toxicity than the mean (p<0-001). Ofthese newer drugs, maprotiline had a fatal toxicity index similar to that Sources ofinformation and methods of the older tricyclic antidepressants, while the other newly The statistical sources used list drugs under their generic and proprietary http://www.bmj.com/ introduced drugs had lower toxicity indices, with those for names.
    [Show full text]
  • Pindolol, and Slow-Release Propranolol
    BRITISH MEDICAL JOURNAL VOLUME 285 13 NOVthER 1982 1387 Ambulatory blood pressure during once-daily randomised double-blind administration of atenolol, metoprolol, pindolol, and slow-release propranolol J S FLORAS, J V JONES, M 0 HASSAN, P SLEIGHT Abstract beta-blockers suggests, however, that they might not reduce blood pressure effectively for a full 24 hours.5-7 Most studies of Intra-arterial ambulatory blood pressure was measured once-daily beta-blockade have measured clinic blood pressure at over 24 hours, in 34 patients with newly diagnosed rest or during exercise, or both.8- 1 Atenolol, metoprolol, hypertension, both before and after double-blind ran- pindolol, and slow-release propranolol, among others, have been domisation to treatment with atenolol (n=9), metoprolol studied in this fashion. (n=9), pindolol (n=9), or propranolol in its slow-release Continuous ambulatory monitoring, which gives a direct, form (n=7). The dosage of each drug was adjusted at beat-to-beat measure of blood pressure, has advantages over monthly clinic visits until satisfactory control of blood clinic cuff records in assessing the extent and duration of effect pressure was achieved (140/90 mm Hg or less by cuff) of antihypertensive agents when subjects are at liberty to go or the maximum dose in the study protocol was reached. about their normal daily activities.'9 Earlier, we found that ateno- A second intra-arterial recording was made after these lol taken once daily for two to nine months effectively reduced drugs had been taken once daily at 0800 for three to eight ambulatory blood pressure for up to 28 hours after the last dose months (mean 50± SD 1 4) and was started four hours was administered.20 Other beta-blocking agents have been after the last dose.
    [Show full text]
  • Drug-Facilitated Sexual Assault Panel, Blood
    DRUG-FACILITATED SEXUAL ASSAULT PANEL, BLOOD Blood Specimens (Order Code 70500) Alcohols Analgesics, cont. Anticonvulsants, cont. Antihistamines, cont. Ethanol Phenylbutazone Phenytoin Cyclizine Amphetamines Piroxicam Pregabalin Diphenhydramine Amphetamine Salicylic Acid* Primidone Doxylamine BDB Sulindac* Topiramate Fexofenadine Benzphetamine Tapentadol Zonisamide Guaifenesin Ephedrine Tizanidine Antidepressants Hydroxyzine MDA Tolmetin Amitriptyline Loratadine MDMA Tramadol Amoxapine Oxymetazoline* Mescaline* Anesthetics Bupropion Pyrilamine Methcathinone Benzocaine Citalopram Tetrahydrozoline Methamphetamine Bupivacaine Clomipramine Triprolidine Phentermine Etomidate Desipramine Antipsychotics PMA Ketamine Desmethylclomipramine 9-hydroxyrisperidone Phenylpropanolamine Lidocaine Dosulepin Aripiprazole Pseudoephedrine Mepivacaine Doxepin Buspirone Analgesics Methoxetamine Duloxetine Chlorpromazine Acetaminophen Midazolam Fluoxetine Clozapine Baclofen Norketamine Fluvoxamine Fluphenazine Buprenorphine Pramoxine* Imipramine Haloperidol Carisoprodol Procaine 1,3-chlorophenylpiperazine (mCPP) Mesoridazine Cyclobenzaprine Rocuronium Mianserin* Norclozapine Diclofenac Ropivacaine Mirtazapine Olanzapine Etodolac Antibiotics Nefazodone Perphenazine Fenoprofen Azithromycin* Nordoxepin Pimozide Hydroxychloroquine Chloramphenicol* Norfluoxetine Prochlorperazine Ibuprofen Ciprofloxacin* Norsertraline Quetiapine Ketoprofen Clindamycin* Nortriptyline Risperidone Ketorolac Erythromycin* Norvenlafaxine Thioridazine Meclofenamic Acid* Levofloxacin* Paroxetine
    [Show full text]
  • Migraine Headache Prophylaxis Hien Ha, Pharmd, and Annika Gonzalez, MD, Christus Santa Rosa Family Medicine Residency Program, San Antonio, Texas
    Migraine Headache Prophylaxis Hien Ha, PharmD, and Annika Gonzalez, MD, Christus Santa Rosa Family Medicine Residency Program, San Antonio, Texas Migraines impose significant health and financial burdens. Approximately 38% of patients with episodic migraines would benefit from preventive therapy, but less than 13% take prophylactic medications. Preventive medication therapy reduces migraine frequency, severity, and headache-related distress. Preventive therapy may also improve quality of life and prevent the progression to chronic migraines. Some indications for preventive therapy include four or more headaches a month, eight or more headache days a month, debilitating headaches, and medication- overuse headaches. Identifying and managing environmental, dietary, and behavioral triggers are useful strategies for preventing migraines. First-line med- ications established as effective based on clinical evidence include divalproex, topiramate, metoprolol, propranolol, and timolol. Medications such as ami- triptyline, venlafaxine, atenolol, and nadolol are probably effective but should be second-line therapy. There is limited evidence for nebivolol, bisoprolol, pindolol, carbamazepine, gabapentin, fluoxetine, nicardipine, verapamil, nimodipine, nifedipine, lisinopril, and candesartan. Acebutolol, oxcarbazepine, lamotrigine, and telmisartan are ineffective. Newer agents target calcitonin gene-related peptide pain transmission in the migraine pain pathway and have recently received approval from the U.S. Food and Drug Administration; ​​​how- ever, more studies of long-term effectiveness and adverse effects are needed. The complementary treatments petasites, feverfew, magnesium, and riboflavin are probably effective. Nonpharmacologic therapies such as relaxation training, thermal biofeedback combined with relaxation training, electromyographic feedback, and cognitive behavior therapy also have good evidence to support their use in migraine prevention. (Am Fam Physician. 2019; 99(1):17-24.
    [Show full text]
  • Drug and Medication Classification Schedule
    KENTUCKY HORSE RACING COMMISSION UNIFORM DRUG, MEDICATION, AND SUBSTANCE CLASSIFICATION SCHEDULE KHRC 8-020-1 (11/2018) Class A drugs, medications, and substances are those (1) that have the highest potential to influence performance in the equine athlete, regardless of their approval by the United States Food and Drug Administration, or (2) that lack approval by the United States Food and Drug Administration but have pharmacologic effects similar to certain Class B drugs, medications, or substances that are approved by the United States Food and Drug Administration. Acecarbromal Bolasterone Cimaterol Divalproex Fluanisone Acetophenazine Boldione Citalopram Dixyrazine Fludiazepam Adinazolam Brimondine Cllibucaine Donepezil Flunitrazepam Alcuronium Bromazepam Clobazam Dopamine Fluopromazine Alfentanil Bromfenac Clocapramine Doxacurium Fluoresone Almotriptan Bromisovalum Clomethiazole Doxapram Fluoxetine Alphaprodine Bromocriptine Clomipramine Doxazosin Flupenthixol Alpidem Bromperidol Clonazepam Doxefazepam Flupirtine Alprazolam Brotizolam Clorazepate Doxepin Flurazepam Alprenolol Bufexamac Clormecaine Droperidol Fluspirilene Althesin Bupivacaine Clostebol Duloxetine Flutoprazepam Aminorex Buprenorphine Clothiapine Eletriptan Fluvoxamine Amisulpride Buspirone Clotiazepam Enalapril Formebolone Amitriptyline Bupropion Cloxazolam Enciprazine Fosinopril Amobarbital Butabartital Clozapine Endorphins Furzabol Amoxapine Butacaine Cobratoxin Enkephalins Galantamine Amperozide Butalbital Cocaine Ephedrine Gallamine Amphetamine Butanilicaine Codeine
    [Show full text]
  • Parkinson's Disease Diagnosis and Management in Primary And
    DRAFT FOR FIRST CONSULTATION Full version of NICE Guideline No. X Parkinson’s Disease Diagnosis and Management in Primary and Secondary Care. Developed by National Collaborating Centre for Chronic Conditions Royal College of Physicians Parkinson’s disease: full guideline DRAFT (August 2005) Page 1 of 277 DRAFT FOR FIRST CONSULTATION Table of contents Guideline Development Group Membership ................................................5 Acknowledgments: .......................................................................................6 Preface.........................................................................................................7 1. Introduction ..................................................................................................8 Background ..................................................................................................8 Modern Definition .........................................................................................8 Health and resource implications .................................................................8 2. Methodology ..............................................................................................10 Aim .............................................................................................................10 Scope .........................................................................................................10 Methodology...............................................................................................12 3. Key Messages
    [Show full text]
  • Tcas Versus Placebo - New Studies in the Guideline Update
    TCAs versus placebo - new studies in the guideline update Comparisons Included in this Clinical Question Amitriptyline vs placebo Clomipramine vs placebo Dosulepin (dothiepin) vs placebo AMSTERDAM2003A LARSEN1989 FERGUSON1994B BAKISH1992B PECKNOLD1976B ITIL1993 BAKISH1992C RAMPELLO1991 MINDHAM1991 BREMNER1995 THOMPSON2001B CLAGHORN1983 CLAGHORN1983B FEIGHNER1979 GELENBERG1990 GEORGOTAS1982A GOLDBERG1980 HICKS1988 HOLLYMAN1988 HORMAZABAL1985 HOSCHL1989 KLIESER1988 LAAKMAN1995 LAPIERRE1991 LYDIARD1997 MYNORSWALLIS1995 MYNORSWALLIS1997 REIMHERR1990 RICKELS1982D RICKELS1985 RICKELS1991 ROFFMAN1982 ROWAN1982 SMITH1990 SPRING1992 STASSEN1993 WILCOX1994 16 Imipramine vs placebo BARGESCHAAPVELD2002 BEASLEY1991B BOYER1996A BYERLEY1988 CASSANO1986 CASSANO1996 CLAGHORN1996A COHN1984 COHN1985 COHN1990A COHN1992 COHN1996 DOMINGUEZ1981 DOMINGUEZ1985 DUNBAR1991 ELKIN1989 ENTSUAH1994 ESCOBAR1980 FABRE1980 FABRE1992 FABRE1996 FEIGER1996A FEIGHNER1980 FEIGHNER1982 FEIGHNER1983A FEIGHNER1983B FEIGHNER1989 FEIGHNER1989A FEIGHNER1989B FEIGHNER1989C FEIGHNER1992B FEIGHNER1993 FONTAINE1994 GELENBERG2002 GERNER1980B HAYES1983 ITIL1983A KASPER1995B KELLAMS1979 LAIRD1993 LAPIERRE1987 LECRUBIER1997B LIPMAN1986 LYDIARD1989 MARCH1990 17 MARKOWITZ1985 MENDELS1986 MERIDETH1983 Nortriptyline vs placebo NANDI1976 GEORGOTAS1986A NORTON1984 KATZ1990 PEDERSEN2002 NAIR1995 PESELOW1989 WHITE1984A PESELOW1989B PHILIPP1999 QUITKIN1989 RICKELS1981 RICKELS1982A RICKELS1987 SCHWEIZER1994 SCHWEIZER1998 SHRIVASTAVA1992 SILVERSTONE1994 SMALL1981 UCHA1990 VERSIANI1989 VERSIANI1990
    [Show full text]
  • IEHP Dualchoice Cal Mediconnect Formulary Maintenance Drug List
    IEHP DualChoice Cal MediConnect (Medicare-Medicaid Plan) Formulary Maintenance Drug List The following formulary medications may be approvable up to a three-month supply. Certain medications on this list may require prior approval from the plan based on existing criteria before being covered. For coverage information please see our formulary located on our website. BRAND GENERIC STREGTH DOSAGE FORM ABACAVIR ABACAVIR SULFATE 300 MG TABLET ABACAVIR ABACAVIR SULFATE 20 MG/ML SOLUTION TRIUMEQ ABACAVIR SULFATE/DOLUTEGRAVIR 600-50-300 TABLET SODIUM/LAMIVUDINE ABACAVIR-LAMIVUDINE ABACAVIR SULFATE/LAMIVUDINE 600-300MG TABLET ABACAVIR-LAMIVUDINE- ABACAVIR SULFATE/LAMIVUDINE/ZIDOVUDINE 150-300 MG TABLET ZIDOVUDINE TYMLOS ABALOPARATIDE 80MCG/DOSE PEN INJCTR ORENCIA ABATACEPT 125 MG/ML SYRINGE ORENCIA CLICKJECT ABATACEPT 125 MG/ML AUTO INJCT ORENCIA ABATACEPT 50MG/0.4ML SYRINGE ORENCIA ABATACEPT 87.5MG/0.7 SYRINGE VERZENIO ABEMACICLIB 50 MG TABLET VERZENIO ABEMACICLIB 100 MG TABLET VERZENIO ABEMACICLIB 150 MG TABLET VERZENIO ABEMACICLIB 200 MG TABLET ABIRATERONE ACETATE ABIRATERONE ACETATE 500 MG TABLET ABIRATERONE ACETATE ABIRATERONE ACETATE 250 MG TABLET YONSA ABIRATERONE ACETATE, SUBMICRONIZED 125 MG TABLET CALQUENCE ACALABRUTINIB 100 MG CAPSULE ACAMPROSATE CALCIUM ACAMPROSATE CALCIUM 333 MG TABLET DR ACARBOSE ACARBOSE 25 MG TABLET ACARBOSE ACARBOSE 50 MG TABLET ACARBOSE ACARBOSE 100 MG TABLET ACEBUTOLOL HCL ACEBUTOLOL HCL 200 MG CAPSULE ACEBUTOLOL HCL ACEBUTOLOL HCL 400 MG CAPSULE ACETAZOLAMIDE ER ACETAZOLAMIDE 500 MG CAPSULE ER ACETAZOLAMIDE
    [Show full text]